RSS TScan Therapeutics To Offer $30 Mln Pre-funded Warrants At 37% Premium

Currently reading:
 RSS TScan Therapeutics To Offer $30 Mln Pre-funded Warrants At 37% Premium

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
7,782
Likes
1,922
Credits
33,162©
Cash
0$
TScan Therapeutics, Inc. (TCRX), a company at the forefront of clinical-stage biotechnology, announced on Thursday its entry into a securities purchase agreement with Lynx1 Capital Management LP and an associated investment fund. This agreement involves the sale of pre-funded warrants, amounting to roughly $30 million. These warrants allow for the purchase of up to 7.5 million shares at a price of $4.00 each.

Each pre-funded warrant is convertible into one share of voting common stock at an exercisable price of $0.0001 per share, offering a 37% premium. This offering further stands at a 34% premium compared to the 10-day volume-weighted average closing price.

The transaction is anticipated to conclude around December 27, 2024. The gross proceeds of $30 million are projected to support the company's operational requirements through the first quarter of 2027.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips
Top Bottom